$13.250
+0.011 (+0.08%)Al cierre
Noticias de CCRN
Eventos de CCRN
Cross Country Healthcare Signs Exclusive 36-Month Partnership with Optime
Cross Country Healthcare announced an exclusive 36-month partnership to bring the Optime workforce strategy and planning solution into Intellify, Cross Country's workforce intelligence platform. "Health systems do not need more dashboards. They need better decisions, better visibility and better operational control," said Kevin Clark, Co-Founder and Chief Executive Officer of Cross Country. "Optime strengthens our ability to help clients manage labor more intelligently and more proactively, and it expands the value we are building through Intellify and across the enterprise."
Benchmark Downgrades Cross Country Healthcare to Hold
Benchmark analyst Bill Sutherland downgraded Cross Country Healthcare to Hold from Buy after the company agreed to be acquired by Knox Lane for $13.25 per share.
Company Reports Q1 Revenue of $241.06M, Exceeding Expectations
Reports Q1 revenue $241.06M, consensus $236.84M. "We ended the first quarter with positive momentum, underscored by sequential revenue growth and several new MSP wins and expansions," said Kevin C. Clark, Co-Founder, Chairman and Chief Executive Officer. He continued, "As we await the closing of the pending transaction with Knox Lane in the third quarter, our focus remains on disciplined execution and advancing our technology initiatives to support our clients' evolving workforce needs." The company added: "In consideration of the proposed Merger, the Company is canceling its earnings conference call to discuss its first quarter 2026 financial results, which was previously scheduled to be held on May 7."
Citizens Analyst Downgrades Cross Country Healthcare to Market Perform
Citizens analyst Constantine Davides downgraded Cross Country Healthcare to Market Perform from Outperform after the company agreed to be acquired by Knox Lane for $13.25 per share.
Wedbush Downgrades Cross Country Healthcare to Neutral, Price Target Cut to $13.25
Wedbush analyst Michael Piccolo downgraded Cross Country Healthcare to Neutral from Outperform with a price target of $13.25, down from $15, after the company entered into an agreement to be acquired by Knox Lane for $13.25 per share.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.